NEWS
NEWS
Drug Discovery World interviews Milner Institute Head of Research
Earlier this year, our Head of Research Dr Nicola McCarthy sat down with Megan Thomas, Multimedia Editor at Drug Discovery World, to explore...
Cambridge Biomedical Campus welcomes Milner Affiliate Cytiva
Global life sciences leader and Milner affiliate Cytiva recently established a footprint in the Jeffrey Cheah Biomedical Centre on the Cambridge...
Milner Institute celebrates success of 2024 Pitch Day and Therapeutics Symposium
Last week, we were delighted to host two sell-out events in Cambridge that brought academics, investors, pharma and biotech companies together. On...
Milner welcomes Flagship Pioneering to learn more about the Institute’s unique model
We were delighted to welcome Flagship Pioneering to the Milner Therapeutics Institute this week. Noubar Afeyan and colleagues from Flagship visited...
Milner Director Tony Kouzarides awarded a knighthood in the King’s Birthday Honours List
We are delighted to share that our Director, Professor Sir Tony Kouzarides – a Professor of Cancer Biology at the University of Cambridge and a...
Milner collaboration develops organoid assays that could help identify new treatments for Crohn’s disease
Work at the Milner Therapeutics Institute in collaboration with Professor Matthias Zilbauer has made a promising step toward identifying more...
Chun Hao Wong joins the Milner Institute as Lead for Functional Genomics Screening Lab
We are delighted to announce that Chun Hao Wong has joined the Milner team as the MTI lead for the new MRC-AstraZeneca-University of Cambridge...
Milner Institute showcases in-house research at the Cambridge Festival
This year the Milner Institute was delighted to take part in the University of Cambridge’s interdisciplinary Cambridge Festival. The Festival takes...
Call announced for project proposals to collaborate with new functional genomics screening laboratory
The functional genomics screening laboratory (FGSL), a joint venture between our Institute at the University of Cambridge, the Medical Research...
Dr Namshik Han featured on Cytiva’s ‘Discovery Matters’ podcast
We are delighted that our Head of Computational Biology and AI, Dr Namshik Han, was featured on Cytiva’s ‘Discovery Matters' podcast series last...
Milner Bio-incubator “Frame Shift” launches second hub in Cambridge city centre
We are delighted to announce that our Frame Shift Bio-incubator has expanded this month, with the opening of a second hub in the city centre, based...
Milner Institute establishes collaboration with the Korea Research Institute of Bioscience and Biotechnology (KRIBB)
Last week colleagues from the Milner Institute and Korea Research Institute of Bioscience and Biotechnology (KRIBB) celebrated the signing of a new...
Milner Therapeutics Institute to house world-class functional genomics laboratory, in new partnership with AstraZeneca and the Medical Research Council
We are delighted to announce a new partnership with AstraZeneca and the Medical Research Council (MRC) that will establish a new state-of-the-art...
Pathania collaboration awarded £1.5m to research childhood brain tumours
We are delighted to share that the Pathania Lab join a team of researchers who have been awarded £1.5 million in The Brain Tumour Charity's Quest...
Takeda and Sanofi join Milner Therapeutics Consortium
We are excited to announce that two new pharma partners — Takeda and Sanofi — have joined the Milner Consortium in the past month. Now with 14...
A full house at eighth Milner Therapeutics Symposium
We were excited to welcome ∼500 delegates at West Road Concert Hall for our annual Symposium on July 5th, with a further 300+ UK and international...
Multiple Milner affiliates recognised at Cambridge Independent Science and Technology Awards
We are delighted that several of our affiliated companies were recognised at the 2023 Cambridge Independent Science & Technology Awards last...
Dr Cathy Tralau-Stewart appointed Executive Director of the Milner Therapeutics Institute
We are delighted to welcome Dr Cathy Tralau-Stewart as the new Executive Director at the Milner Therapeutics Institute. Cathy will work alongside...
Milner welcomes new Head of Target Discovery
We are delighted to welcome Dr Erica Bello as the new Head of Target Discovery at the Milner Therapeutics Institute. Erica brings to the team broad...
Milner Institute collaborates to launch Cambridge AI Club for Biomedicine
The AI Club for Biomedicine, launched earlier this month, is a new initiative created to bring together the biomedical AI and machine learning...
Milner Institute announces strategic collaboration with NC3Rs
We are delighted to announce a new collaboration with the NC3Rs this month, which has been established to help NC3Rs-funded researchers translate...
Milner affiliate STORM Therapeutics initiate phase I clinical trials
Congratulations to Milner affiliated company STORM Therapeutics, who have announced the start of phase I clinical trials with their first-in-class...
MSD joins Milner Therapeutics Consortium
This month we are excited to announce that MSD has joined the Milner Therapeutics Consortium as our 12th pharma partner. This coincides with the...
Milner pharma partner visit to Barcelona affiliated institutes
A long-term priority for the Milner is to share our experience of working with industry with other academic institutes, with the goal of fostering...
Pathania group receive £1m to investigate children’s brain tumours
We are delighted that Dr Manav Pathania and team, who are based at the Milner Therapeutics Institute, have been awarded ~£1 million from Cancer...
Video showcase of Milner collaborations with CRUK Cambridge Centre
In May 2021, the Milner Institute launched a rapid response data analysis call, led by Dr Rebecca Harris and Dr Namshik Han. The call sought...
Milner Institute recognized at Vice-Chancellor’s Awards for Research, Impact and Engagement
We were delighted to receive an award at the Vice-Chancellor's Awards for Research, Impact and Engagement last week. Milner Directors Tony...
Head of Entrepreneurship joins Milner team
We are delighted to announce that Alexandra Huener has joined the Milner team as the Head of Entrepreneurship. This exciting new role has been...
Milner welcomes paediatric patients for Patient Research & Science day
The Milner team enjoyed an institute visit with a difference last week, as we welcomed a group of children for Inflammatory Bowel Disease (IBD)...
Milner Institute celebrates success of first hybrid Therapeutics Symposium
Our first ever hybrid Therapeutics Symposium was held at the end of June and we were thrilled to welcome over 350 delegates at West Road Concert...
AI drug target discovery company co-founded by Namshik Han receives £1.4 million pre-seed investment
CardiaTec, a company co-founded by Milner Head of Computational Biology Dr Namshik Han, has secured £1.4 million pre-seed investment to...
Deputy Director Kathryn Chapman receives CEO Today Business Women of the Year Award
The CEO Today Business Women of the Year Awards 2022 edition has been published this week, and we're delighted that Milner Deputy Director Kathryn...
Milner – LifeArc strategic partnership extended for five years
We are thrilled to announce that the Milner collaboration with the medical research charity LifeArc has been expanded into a 5-year strategic...
Milner Institute wins award for innovation at Cambridge Independent Science and Technology Awards
We are honoured to have been announced as highly commended in the Innovation category of the 2022 Cambridge Independent Science & Technology...
Milner Institute announced as finalist in the Cambridge Independent Science and Technology Awards
We are delighted that the Milner Therapeutics Institute has been announced as a finalist for the Award for Innovation in the 2021-2022 Cambridge...
Milner Therapeutics Institute promoted to Affiliated Institute of CRUK Cambridge Centre
We are delighted to announce that, with the renewal of the CRUK Cambridge Centre this year, the Milner will become an Affiliated Institute,...
MTI welcomes George Freeman MP, to learn how Cambridge is leading innovation in life sciences
We were delighted to welcome George Freeman MP, the Parliamentary under Secretary of State in the Department for Business, Energy and Industrial...
Director Tony Kouzarides receives Cyprus Excellence in Science award
The President of Cyprus, Nicos Anastasiades, presented our Director Tony Kouzarides with the prestigious Excellence in Science Award this week, on...
Milner Institute wins OBN Award for Most Impactful Business Support Organisation
This week, Deputy Director Kathryn Chapman and Communications Manager Nikki Mann represented the Milner team at the OBN Awards in Oxford, and we are...
KPBMA bring international partners to Milner affiliate network
We are delighted to share that KPBMA (Korea Pharmaceutical and Bio-Pharma Manufacturers Association) has joined as an Affiliated Organization of...
Astellas join Milner Therapeutics Consortium
We are delighted to announce that Astellas have joined the Milner Therapeutics Consortium as our 11th pharma partner. Astellas, a global...
Milner Institute announced as finalist for OBN Award
We are proud to announce that the Milner Therapeutics Institute has been shortlisted for a 2021 OBN Award in the category for Most Impactful...
Milner collaboration uncovers promising target for new drug development
Research in the Tzelepis lab, in collaboration with scientists from the Wellcome Sanger Institute and Harvard University, has identified a protein...
Milner group use combination of computational biology and machine learning to create comprehensive map of proteins involved in SARS-CoV-2 infection
Namshik Han's group at the Milner Therapeutics Institute, have identified 200 approved drugs predicted to work against COVID-19 – of which only 40...
Connect: Health Tech is launched
We are excited to announce that the University of Cambridge has launched the Connect: Health Tech microsite and online community platform, as part...
Onco-Innovation collaborations awarded from pump prime call
Last month, the Onco-Innovation Programme — part of the CRUK Cambridge Centre and managed by our own Dr Rebecca Harris — launched a new rapid...
Milner collaboration targets RNA-modifying enzymes as promising anti-cancer strategy
Work at the Milner Therapeutics Institute by Director Tony Kouzarides and Kostas Tzelepis in collaboration with Storm Therapeutics has made a...
Autophagy targets in neurodegeneration
We are excited to announce a new collaboration which has been set up through the Milner Therapeutics Consortium to investigate autophagy targets in...
Affiliate Companies showcase their work
As we reach the end of what has been the most challenging and difficult year so far, we want to take the time to celebrate the achievements of our...
Milner Consortium reaches 10
We are excited to announce that two new pharma partners — Eli Lilly and Company and Bristol Myers Squibb — have joined the Milner Consortium in the...